Benzene and Acute Myeloid Leukemia: Clinical Evidence Review

Legacy of General Health and Science Information

The legacy of general health and science information has long served as a foundation for public understanding of environmental risks. Within this broad context, historical awareness of chemical hazards has evolved from basic safety guidelines to more nuanced considerations of exposure pathways. This heritage provides a critical baseline for examining specific occupational scenarios where chemical contact may be elevated beyond typical environmental levels. Transitioning from this general framework, attention now turns to the occupational setting, where sustained exposure to industrial solvents and byproducts presents distinct challenges. Among these, benzene has been a subject of particular scrutiny due to its widespread use in manufacturing processes. The shift from general health advisories to focused occupational concern requires careful examination of exposure duration, concentration levels, and workplace practices that differentiate routine environmental contact from industrial scenarios. This pivot acknowledges that while general health information establishes foundational risk awareness, occupational environments demand specialized evaluation of exposure parameters and their potential health implications.

Occupational Exposure and Benzene as a Myelotoxin

Benzene is a recognized myelotoxin and carcinogen, with chronic exposure linked to an increased risk of acute myeloid leukemia (AML) (https://pubmed.ncbi.nlm.nih.gov/34069279/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with elevated AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). Previous studies have established a causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/). The mode of action for AML development is anticipated to include multiple earlier key events, such as hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical adverse outcomes, including morbidity and mortality from myelodysplastic syndromes (MDS) and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Mechanistic pathways linking benzene to AML include genotoxic effects, oxidative stress and inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, genetic alterations alone are insufficient to fully justify several phenomena influencing the onset of hematologic malignancies, suggesting epigenetic effects play a role (https://pubmed.ncbi.nlm.nih.gov/34069279/). Benzene is also acknowledged as a risk factor for solid cancers and other hematological neoplasms, including myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Epidemiological Evidence and Exposure-Response Relationship

Epidemiological evidence supports an exposure-response relationship between benzene and AML. A meta-regression model integrating data from six human AML studies, three human leukemia studies, ten human biomarker studies, and four experimental animal studies estimated the exposure-response curve for benzene and AML (https://pubmed.ncbi.nlm.nih.gov/34906966/). A linear meta-regression model with intercept best predicted AML risks after cross-validation (https://pubmed.ncbi.nlm.nih.gov/34906966/). Additionally, a meta-analysis of 25 studies found an increased risk of childhood AML associated with benzene exposure, with an odds ratio of 1.22 per 1 μg/m³ increase (95% CI: 1.02-1.46) (https://pubmed.ncbi.nlm.nih.gov/41485753/). This same analysis reported elevated risks for all childhood cancers (OR: 1.12, 95% CI: 1.02-1.22) linked to benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). The timeline between benzene exposure and documented harm varies. Occupational studies have linked exposure at levels of 10 ppm or more to increased AML risk, with the mode of action involving early hematotoxic and genotoxic events observable in peripheral blood (https://pubmed.ncbi.nlm.nih.gov/33429013/). These early events precede the development of MDS and AML, which are apical outcomes (https://pubmed.ncbi.nlm.nih.gov/33429013/). The Swiss National Cohort study examined mortality from lymphohaematopoietic cancers in relation to occupational benzene exposure, using a quantitative job-exposure matrix applied to census-reported occupations (https://pubmed.ncbi.nlm.nih.gov/38727681/). This study contributes to the evidence base on long-term mortality risks.

Causation Considerations and Adequacy of Warnings

For affected patients, causation considerations include the level and duration of benzene exposure, the presence of early hematotoxic effects, and the latency period between exposure and AML diagnosis. The established causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/) supports the need for adequate warnings. The evidence indicates that benzene is a myelotoxin that can augment the risk for AML onset (https://pubmed.ncbi.nlm.nih.gov/34069279/). The incorporation of key event information, such as hematotoxicity and genetic toxicity, should modify risk models to better predict adverse outcomes (https://pubmed.ncbi.nlm.nih.gov/33429013/). Adequacy of warnings regarding benzene and AML is informed by the recognition of benzene as a carcinogen and myelotoxin. The evidence underscores that chronic exposure to benzene is a risk factor for AML (https://pubmed.ncbi.nlm.nih.gov/34069279/), and occupational exposure at levels of 10 ppm or more has been associated with increased risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). The exposure-response relationship has been quantified through meta-regression (https://pubmed.ncbi.nlm.nih.gov/34906966/), and childhood exposure has been linked to elevated AML risk (https://pubmed.ncbi.nlm.nih.gov/41485753/). These findings highlight the importance of clear warnings about the hematologic risks of benzene exposure.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the relationship between benzene exposure and acute myeloid leukemia?

Benzene is a recognized myelotoxin and carcinogen. Chronic exposure to benzene has been linked to an increased risk of acute myeloid leukemia (AML) (https://pubmed.ncbi.nlm.nih.gov/34069279/). Occupational exposure at levels of 10 ppm or more has been associated with elevated AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/).

What are the mechanistic pathways linking benzene to AML?

Mechanistic pathways include genotoxic effects, oxidative stress and inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). Additionally, epigenetic effects may play a role (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Is there an exposure-response relationship between benzene and AML?

Yes, epidemiological evidence supports an exposure-response relationship. A meta-regression model estimated the exposure-response curve for benzene and AML (https://pubmed.ncbi.nlm.nih.gov/34906966/). Childhood benzene exposure has also been linked to elevated AML risk (https://pubmed.ncbi.nlm.nih.gov/41485753/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.